Blend Therapeutics Inc., a Watertown-based biopharmaceutical company seeking new cancer treatments, said that it has appointed pharmaceutical industry veteran Richard Wooster as its chief scientific officer.
Wooster will be responsible for leading the company’s research and development strategy and clinical operations as its lead drug candidates advance toward clinical development, Blend Therapeutics said in a press release.
Before joining Blend, Wooster was vice president and head of the Cancer Metabolism Discovery Performance Unit in Oncology at GlaxoSmithKline.
“We are extremely pleased that Richard has joined our team to lead the discovery and development of Blend’s innovative drug candidates, which in the near term are focused on the treatment of cancer, an area of Richard’s core expertise,” Blend Therapeutics president and chief executive Mark Iwicki said in a statement. “His extensive leadership, strategic, and technical experience at the highest levels in cancer genetics and pharmaceutical drug discovery and development will be a great asset to the company to drive innovation and our partnering activities.”